PDGF Signalling Is Required for Gastrulation of Xenopus Laevis

Total Page:16

File Type:pdf, Size:1020Kb

PDGF Signalling Is Required for Gastrulation of Xenopus Laevis Development 121, 3099-3110 (1995) 3099 Printed in Great Britain © The Company of Biologists Limited 1995 PDGF signalling is required for gastrulation of Xenopus laevis Paris Ataliotis1, Karen Symes1, Margaret M. Chou1, Lap Ho2 and Mark Mercola1,* 1Department of Cell Biology, Harvard Medical School, 25 Shattuck Street, Boston MA 02115, USA 2Department of Pharmacology, Cornell University Medical College, 1300 York Avenue, New York NY 10021, USA *Author for correspondence SUMMARY During Xenopus gastrulation, platelet-derived growth closure of the blastopore, leads to abnormal gastrulation factor (PDGF) receptor-α is expressed in involuting and a loss of anterior structures. Convergent extension is marginal zone cells which migrate over ectodermal cells not inhibited in these embryos, but rather, involuting meso- expressing PDGF-A. To investigate the role of PDGF sig- dermal cells fail to adhere to the overlying ectoderm. PDGF nalling during this process, we have generated a novel point may therefore be required for mesodermal cell-substratum mutant of PDGF receptor-α analogous to the W37 mutation interaction. of c-kit. This molecule is a specific, potent, dominant inhibitor of PDGF signalling in vivo. Injection of RNA encoding this protein into Xenopus embryos prevents Key words: Xenopus, PDGF, gastrulation, dominant negative INTRODUCTION to block colony stimulating factor-1-dependent transformation of Rat-2 cells (Reith et al., 1993). Gastrulation involves a complex, co-ordinated series of cell Here we demonstrate that a point mutant of Xenopus movements that give rise to the body plan in all vertebrates. In PDGFR-α analogous to the W37 mutation of c-kit lacks the frog, Xenopus laevis, this process begins with the involu- detectable kinase activity and acts in a dominant negative tion of cells on the dorsal side of the embryo. Apical constric- manner to inhibit signalling by the wild-type receptor in vivo. tion of the outermost epithelial cells gives rise to the blasto- We have used this mutant receptor to disrupt PDGF-A sig- pore lip and precedes the involution of mesodermal cells from nalling in the Xenopus embryo and show that PDGF is the marginal zone (for review, see Keller, 1991). As these necessary for normal gastrulation but is not required for mesodermal cells involute, they migrate over the inner surface mesoderm induction. We further demonstrate that defects arise of the blasotcoel roof toward the future anterior end of the due to the inappropriate behaviour of mesodermal cells and embryo. The migration and fate of these involuting cells are discuss possible mechanisms that may lead to these abnormal- presumed to be controlled by extracellular signals, although ities. these are as yet poorly understood. A candidate signalling molecule that may be involved in gastrulation is platelet-derived growth factor A (PDGF-A, MATERIALS AND METHODS Jones et al., 1993). We now show by in situ hybridisation that PDGF-A mRNA is present in the blastocoel roof of the early Embryos gastrula stage Xenopus embryo. This tissue forms the substra- Xenopus embryos were fertilized in vitro and chemically dejellied tum for the migration of marginal zone cells which express the using 2% cysteine-HCl, pH 7.8, then maintained in 10% Marc’s receptor for PDGF-A, PDGFR-α. modified Ringer’s (0.1× MMR, Peng, 1991) at temperatures between In order to assess the role of PDGF-A during Xenopus gas- 13 and 20°C until they had reached the appropriate stages (according trulation, we have generated a novel, dominant negative mutant to Nieuwkoop and Faber, 1967) for injection or analysis. Microinjec- of its receptor, PDGFR-α. This mutant is based on the W37 tion was performed in a solution of 3% Ficoll in 1× MMR using mutation of the homologous receptor tyrosine kinase c-kit bevelled, glass capillary needles. Xenopus animal poles were (Nocka et al., 1990; Reith et al., 1990). The amino acid residue explanted at stage 8 and maintained in 75% MMR/0.1% bovine serum affected in W37 is conserved throughout the PDGF receptor albumin until control embryos had reached the required stage. Growth factors (50 ng/ml PDGF-AA, Gibco-BRL, 500 ng/ml bFGF, Amgen family and is therefore thought to be essential for function. and 2 U/ml βA activin, from transfected COS cell supernatant) were 37 Indeed, a mutation of c-fms corresponding to W c-kit added directly to this medium immediately after explants were abolishes the kinase activity of this receptor. More importantly, excised. Exogastrulae were induced by manually removing the the W-like fms mutants can act in a trans-dominant manner to vitelline membrane of embryos at stage 8 and transferring to 1× MMR prevent tyrosine phosphorylation of the wild-type receptor and in dishes coated with 1% agarose in 1× MMR. β-galactosidase activity 3100 P. Ataliotis and others was detected by standard procedures using the chromogenic substrate slides and hybridised to 35S-labeled RNA probes as described X-gal. (O’Keefe et al., 1991). Serial sections were hybridised to sense and antisense cRNA probes for Xenopus PDGF-A (Mercola et al., 1988) In situ hybridisation and PDGFR-α (Jones et al., 1993). In no case was a hybridisation For radioactive in situ hybridisation experiments, albino embryos signal detected with sense probes. After washing, slides were coated were fixed in 4% paraformaldehyde in 70% PBS for 1 hour at 4°C with Kodak NTB-2 emulsion and exposed for 2 weeks at 4°C. For prior to embedding in paraffin. 8 µm sections were mounted on glass whole-mount in situ hybridisation, pigmented embryos were fixed in Fig. 1. In situ hybridisation of PDGF A and PDGFRα mRNA during the gastrula stages of development. Serial sections of gastrula staged embryos were probed with 35S-labelled antisense PDGF-A and PDGFR-α cRNA probes. PDGF A is expressed in the presumptive ectoderm (A,C,E) and PDGFR-α is expressed in the presumptive mesoderm (B,D,F). (A,B) Sagittal sections through the dorsal midline of a stage 10.25 embryo. (C,D) Parasagittal and (E,F) horizontal sections through a stage 12 embryo. An, animal pole; Vg vegetal pole; D, dorsal; V ventral; A, anterior; P, posterior; bl. blastocoel; a, archenteron. Scale bar, 100 µm. PDGF in Xenopus gastrulation 3101 4% formaldehyde, dehydrated in methanol and then processed as RT-PCR described (Ho et al., 1994). Digoxigenin-labelled cRNA probes for RNA prepared from animal pole explants was reverse transcribed goosecoid and brachyury (Amaya et al., 1993) were the kind gift of using the Stratascript RT-PCR kit (Stratagene) according to manu- Pascal Stein. Embryos were dehydrated in methanol and in some cases facturer’s instructions. cDNA was amplified by PCR in the presence bleached in 10% hydrogen peroxide and cleared in benzyl of [32P]dATP using primers specific for EF1-α and brachyury as alcohol:benzyl benzoate (BA:BB, 1:2) prior to photography. described (Wilson and Melton, 1994). Amplified cDNA products were detected by autoradiography following electrophoresis on 5% Site-directed mutagenesis non-denaturing polyacrylamide gels. A cDNA clone encoding the full-length Xenopus PDGFR-α (Jones et al., 1993) was subcloned as a SacI/BglII fragment into pALTER-1 (Promega) and mutagenised by single-stranded, site-directed mutage- RESULTS nesis according to manufacturer’s instructions. A control frameshift mutation was generated in the full-length receptor by digestion with Distribution of PDGF-A and PDGFR-α in Xenopus KpnI, blunting and re-ligation, causing premature termination in the embryos extracellular domain of the protein at amino acid 159. Using in situ hybridisation we have determined that PDGF-A DNA cloning/RNA production mRNA is distributed uniformly throughout the inner layers of ectodermal cells of the blastocoel roof, but not in the superfi- The wild-type, frameshift and mutagenised Xenopus PDGFR-α were ′ cial layer of early gastrula stage Xenopus embryos (Fig. 1A). subcloned into pGHE2, a vector containing a poly(A) tail and 5 and α 3′ untranslated sequences from Xenopus β-globin (a gift from the late PDGFR- mRNA is localised to the equatorial region of the Peter Hess, Harvard Medical School) such that sense RNA transcripts embryo in cells of the marginal zone (Fig. 1B). During gas- were produced by using T7 RNA polymerase. Capped mRNA was trulation, cells of the marginal zone begin to involute at the made using the mMessage Machine system (Ambion) according to dorsal side of the embryo and move over the inner surface of manufacturer’s instructions. β-galactosidase mRNA containing a the blastocoel roof towards the future anterior end of the nuclear localisation signal was produced from the SP64nuc-βgal embryo (reviewed in Keller, 1991). These cells express plasmid (Vize and Melton, 1991). PDGFR-α and first come into contact with cells expressing PDGF-A shortly after the onset of gastrulation. This comple- Phosphotyrosine detection mentary pattern of ligand and receptor expression persists COS cells were passaged at 1×106 cells per 100 mm dish, 24 hours throughout gastrulation (Fig. 1C-F) and suggests that sig- before DEAE-Dextran transfection. Cells were transfected with either nalling between these cell populations may play an important 10 µg pMT2, 2 µg or 5 µg Xenopus PDGFR-α in pMT2, 10 µg µ α µ role in controlling cellular movement or differentiation during PDGFR-37 in pMT2, 5 g Xenopus PDGFR- plus 5 g PDGFR-37 this process. or 2 µg Xenopus PDGFR-α plus 8 µg PDGFR-37. The total amount µ of DNA was adjusted to 10 g with pMT2 where necessary. After 24 Construction of a dominant negative mutant of hours, cells were transferred to DMEM containing 0.5% calf serum α for a further 24 hours. Cells were treated with 20 ng/ml PDGF-BB PDGFR- (Gibco-BRL) for 10 minutes, washed in ice-cold PBS, then lysed as To examine the function of PDGF-A during Xenopus devel- described previously (Chen and Blenis, 1990).
Recommended publications
  • Enabling Comprehensive Assessments of Drug–Drug Interaction Risks
    R&D Solutions for PHARMA & LIFE SCIENCES PHARMACOVIGILANCE Enabling Comprehensive Assessments of Drug–Drug Interaction Risks Summary Dr. Kevin Lustig, President and CEO of The Assay Depot, Inc., and Dr. Maria Thompson, Principal Consultant, look at the dynamics of drug metabolizing enzymes and transporters and how an understanding of this critical aspect of biology enables assessments of drug–drug interaction risks. In addition, they comment on PharmaPendium®, which includes the DMPK solution with its DDI Risk Calculator, as an important tool in making these assessments successfully. Thanks to its comprehensive data on METs, PharmaPendium offers a unique platform for modeling advanced drug interactions. Abstract Understanding the dynamics of drug metabolizing enzymes and transporters (METs) is critical to successful drug development. MET behavior can significantly impact drug safety. Many factors regulate enzymes and transporters, which in turn affect the pharmacokinetic properties of drugs and mediate drug interactions. Evaluation of drug interaction profiles required detailed in vitro and in vivo studies along with predictive modeling. Thanks to its comprehensive data on METs, PharmaPendium offers a unique platform for modeling advanced drug interactions. This MET data and the ability to predict drug–drug interactions (DDIs) are incredibly valuable for optimized research workflows and accelerated drug development. They enable intelligent, in silico drug design and provide scientists with comprehensive knowledge about drug metabolism, significantly reducing the need for costly and time-consuming lab work and animal models and informing critical decisions on clinical trial design. Introduction Every successful drug discovery and development effort needs to factor in drug efficacy and safety, both of which are intimately linked to drug metabolism.
    [Show full text]
  • July Updates: People and Places
    career news July Updates: People and Places Skills and knowledge transfer alpha-synuclein A53T knock-in model; and commented in a press release, The NC3Rs has awarded a total of £219,339 the continued development of a pre-clinical “The partnership enables Scientist.com this year to three researchers through the model to test LRRk2 kinase inhibitors as a users to easily access innovative rodent 2018 NC3Rs Skills and Knowledge Transfer treatment for PD. models generated with the latest funding competition, designed to promote CRISPR technology.” the post-development uptake of new 3Rs Easi editing approaches. Laura Scullion Hall from The University of Nebraska recently Understanding aging fat the University of Stirling will partner with licensed its Easi-CRISPR gene editing Kristy Townsend, a neurobiologist at the pharmaceutical company GSK to develop technology to Taconic Biosciences. The University of Maine in Orono, has received an online learning platform for research dog CRISPR variant, developed by Masato a three-year $750,000 grant from the handling and welfare. Jonathan Brown from Ohtsuka at the University of Tokyo and American Heart Association to study links the University of Exeter will use the award Channabasavaiah Gurumurthy at the between fat tissue and cardiovascular and to apply the TaiNI wireless EEG recording University of Nebraska, enables the site- metabolic diseases in aging mouse models. technology he developed with scientists at specific insertion of large sequences Recent work from her lab has revealed Eli Lilly through the NC3Rs CRACK IT of DNA, an improvement to previous evidence of “adipose neuropathy”—fat Challenge to dementia research in mice.
    [Show full text]
  • Drug Discovery Chemistry
    Save up to $200! Final Agenda Register by February 23 COVER CHI’s 13th Annual CONFERENCE AT-A-GLANCE PLENARY KEYNOTES SHORT COURSES Drug Discovery AGENDA Plenary April 3-4 Conferences »» Protein-Protein Interactions Keynotes »» Inflammation»&»Autoimmune» Inhibitors Chemistry »» Kinase»Inhibitor»Chemistry Optimizing Small Molecules for Tomorrow's Therapeutics »» GPCR-Targeted Drug Design »» Fragment-Based»Drug» Activity-Based April 2-6, 2018 | San Diego, CA | Hilton San Diego Bayfront Discovery Proteomics: April 4-5 Conferences Protein and »» Ubiquitin»Proteasome»System» Ligand Discovery Inhibitors on a Global Scale CONFERENCE PROGRAMS »» Small»Molecules»for»Cancer» Benjamin F. Cravatt, Immunotherapy PhD, Professor and APRIL 3-4 APRIL 4-5 APRIL 6 Co-Chair, Department »» Macrocyclics»&»Constrained» of Molecular Peptides Medicine, The Protein-Protein Ubiquitin Proteasome Biophysical Approaches »» Targeting»Complex» Scripps Research Membrane»Proteins Institute Interactions System Inhibitors for Drug Discovery April 6 Symposia »» Biophysical»Approaches»for» Lead Optimization Inflammation & Small Molecules for Drug»Discovery for Drug Metabolism Autoimmune Inhibitors Cancer Immunotherapy »» Lead»Optimization»for»Drug» & Safety Metabolism»&»Safety » Targeting Ras » Blood-Brain»Penetrant» Kinase Inhibitor Macrocyclics & Blood-Brain Inhibitors and MYC for the Treatment of Chemistry Constrained Peptides Penetrant Inhibitors HOTEL & TRAVEL Cancer Stephen Fesik, SPONSORSHIP PhD, Professor GCPR-Targeted Targeting Complex Plus Short Courses & EXHIBIT
    [Show full text]
  • Understanding Key Determinants of Drug Activity
    CASE STUDY Dr. Kevin Lustig, President and CEO, The Assay Depot, Inc. Greater San Diego Area Understanding Key Determinants of Drug Activity SUMMARY This article highlights the increasing role that drug metabolism and transport proteins have in the drug approval process. CASE STUDY: The Assay Depot, Inc. The dynamics of drug metabolizing enzymes and transporters is critical to the development of personalized medicine strategies. Abstract / Summary The dynamics of drug metabolizing enzymes and transporters is critical to the develop- ment of personalized medicine strategies. A multitude of factors regulate enzymes and transporters, which in turn affect the pharmacokinetic properties of drugs and medi- ate drug interactions. Evaluation of drug interaction profiles is a critical step in drug development and necessitates detailed in vitro and in vivo studies along with predictive modeling. PharmaPendium® via its Metabolizing Enzymes and Transporters Module provides unprecedented depth of data on drug metabolizing enzymes and transporters and offers a unique platform for modeling advanced drug interactions. This Module will prove to be a valuable resource capable of improving workflows and accelerating devel- opment by enabling intelligent, in silico drug design. By providing scientists with all of the available knowledge about drug metabolism, we can significantly reduce the need for costly and time-consuming lab work and animal models. Requiring these only to answer the true unknowns where no one else has gone before. Introduction Every successful drug discovery and development effort needs to factor in drug efficacy Dr. Kevin Lustig, Author and safety, both of which are intimately linked to drug metabolism. Hence knowledge President & CEO, The Assay Depot Inc.
    [Show full text]
  • Strategic Outsourcing of Pharmaceutical R&D
    CHEMSITRY TODAY Vol 31(4) P. 14-17 / CROS/CMOS Strategic outsourcing of pharmaceutical R&D - Bringing pharma and drug discovery into the information age KEVIN LUSTIG Assay Depot, Inc Corresponding Author KEVIN LUSTIG: Assay Depot, Inc, email: [email protected] KEYWORDS: Outsourcing; innovation; lean; drug; research; discovery ABSTRACT: The centralized model of pharmaceutical development that was used successfully through most of the last century is no longer a good fit. Advances in modern molecular research have changed the playing field to such an extent that the old model is no longer viable. If drug companies can solve the problems of pre-clinical development and deliver a steady stream of new, high- quality compounds to the clinic, then the challenges currently facing pharma will become a thing of the past. The single most likely route to success is through the application of strategic outsourcing, which if done correctly, can dramatically reduce research costs while simultaneously improving research quality. Utilizing new online tools such as research exchanges, a “lean” pharmaceutical company can find and manage a large number of specialist scientific service providers and experts that can bring exactly the right skill set to bear at the right time in the project cycle. INTRODUCTION Few would argue that the Pharmaceutical Industry has been languishing in the doldrums now for well over a decade. Pharmaceutical companies are having to face three major issues involving drug approvals, development costs and patents expirations. Any of these alone would prove a tough nut to crack, but the fact that they are all converging at the same time is creating a perfect storm! • A paucity of new drug approvals: 2010 was one of the worst years on record, with the European Medicines Agency showing only 41 finalized applications, compared to 125 in 2009.
    [Show full text]
  • Marketplaces for Sharing Scientific Data and Outsourcing R&D Activities: the Case Study of the Pharmaceutical, Life Sciences and Bio-Medical Industries
    MARKETPLACES FOR SHARING SCIENTIFIC DATA AND OUTSOURCING R&D ACTIVITIES: THE CASE STUDY OF THE PHARMACEUTICAL, LIFE SCIENCES AND BIO-MEDICAL INDUSTRIES In the present document, we aim to review the main protagonist companies in the field of the outsourcing of biomedical R&D research and in the sharing of scientific data and contract- research consultancy services. This effort is part of a longer-term objective aimed at assessing the current state of the R&D outsourcing market via “marketplace” type of websites, in order to estimate the existing potential competition to the core areas of interest of the VIMMP project. Even though, under the current state of affairs, no direct competitors of VIMMP presently exist (within the restricted field of materials modelling coupled with marketplace and data/software sharing type of functionalities), marketplace websites active in other branches of science and technology can still provide invaluable insight in demonstrating how such R&D commercial operations can be implemented and exploited successfully and profitably. 1. General Introduction to R&D Outsourcing Services Advances in science, technology, and engineering impact our daily lives and fuel economic growth and prosperity. Investment in innovation and R&D drives these advances, and it is the hi-tech companies and their respective industries that dominate global R&D spending. Hardware/software, electronics, automotive, aerospace and defense, telecommunications, and pharmaceutical/biotech all feature as the highest R&D spending industries. The pharmaceutical/biotech industry has the highest levels of R&D outsourcing across hi-tech industries, with its outsourcing growth rate outstripping internal investments. Some large pharmaceutical companies suggest that 40% or more of their R&D spend will be outsourced in the near future, and that clinical operations functions will eventually be outsourced entirely.
    [Show full text]
  • Motility of Acta Protein-Coated Microspheres Driven by Actin Polymerization
    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 4908–4913, April 1999 Biophysics Motility of ActA protein-coated microspheres driven by actin polymerization LISA A. CAMERON*, MATTHEW J. FOOTER†,ALEXANDER VAN OUDENAARDEN‡, AND JULIE A. THERIOT†§¶ *Department of Biological Sciences, Stanford University, Stanford, CA 94305-5020; †Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305-5307; ‡Department of Chemistry, Stanford University, Stanford, CA 94305-5080; and §Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305-5124 Communicated by James A. Spudich, Stanford University School of Medicine, Stanford, CA, March 1, 1999 (received for review January 12, 1999) ABSTRACT Actin polymerization is required for the gen- moving endosomes (J. Heuser, personal communication) and eration of motile force at the leading edge of both lamellipodia phospholipid vesicles (11). Although much is understood and filopodia and also at the surface of motile intracellular about the biochemical mechanisms of catalyzing actin filament bacterial pathogens such as Listeria monocytogenes. Local polymerization in several of these systems (12–14), relatively catalysis of actin filament polymerization is accomplished in little is known about how this local surface catalysis results in L. monocytogenes by the bacterial protein ActA. Polystyrene comet tail formation, force generation, and motility. It is beads coated with purified ActA protein can undergo direc- striking that a variety of biochemical mechanisms for cata- tional movement in an actin-rich cytoplasmic extract. Thus, lyzing local actin polymerization on the surface of a small the actin polymerization-based motility generated by ActA can object (bacterium, virus, or membrane vesicle) all result in the be used to move nonbiological cargo, as has been demon- same type of actin self-organization and movement.
    [Show full text]
  • Collaborative Drug Discovery's 10 Anniversary Community Meeting
    Collaborative Drug Discovery’s 10th Anniversary Community Meeting April 4th, 2014 8am-6pm UCSF Mission Bay Conference Center 1675 Owens St. San Francisco, CA 94158 Please use this Twitter hashtag for the event: #CDDx14 Agenda 7:45 Registration - refreshments in Foyer and Exhibition room 8:15 Opening Remarks - with UCSF Host, Stephanie Robertson and CDD CEO, Barry Bunin Collaborative Workflow: Basic and Advanced Use Cases of CDD Vault 8:20 Charlie Weatherall (CDD) & Anna Spektor (CDD) 9:10 Morning Sessions - moderated by Sylvia Ernst (CDD) The Rockefeller University Compound Screening Library 9:15 J. Fraser Glickman (Rockefeller University) Recent Progress in De-Orphanization of Nuclear Receptors 9:40 Ruo Steensma (Orphagen Pharmaceuticals) 10:05 Morning Break - located in the Foyer and Exhibition room Large small molecules in a Small large molecule world 10:35 Leanna Staben (Genentech) Linking the Molecular Structure of Medicines to their Biological Effects 11:00 Bob Volkmann (Systamedic & Mnemosyne Pharmaceuticals) Panel: Externalized Research - What Makes a Good Partnership? Wisdom from Experts 11:25 Who've "Been There - Done That," moderated by Sylvia Ernst (CDD) 11:50 Lunch - boxed lunches in the Foyer and Exhibition room Optional: “What if CDD had...” provide feedback to our product team (12:35) Kellan Gregory (CDD) 10 Years Evolving Our Collaborative Drug Discovery Vaults 1:05 Barry Bunin (CDD) CDD Vault: Noteworthy recent enhancements and a preview of things to come 1:30 David Blondeau (CDD) & Kellan Gregory (CDD) 2:20 Afternoon sessions - moderated Christopher Lipinski The Tuberculosis Drug Accelerator: A New Paradigm For Drug Discovery 2:25 Jerry Shipps (Tuberculosis Drug Accelerator) The role of NIAID in the development of therapeutics for Infectious Diseases 2:50 Martin John Rogers (NIAID) 3:15 Afternoon Break - located in the Foyer and Exhibition Room Targeting the Immunoproteasome 3:40 Dustin L.
    [Show full text]
  • Helping the Life Science Industry Accelerate R&D
    12 www.sdbj.com AUGUST 16, 2021 SPECIAL REPORT: LIFE SCIENCES Helping the Life Science Industry Accelerate R&D San Diego’s Biotech Boom Backed By Research Institutions and Contract Organizations By NATALLIE ROCHA Local life science companies big and small have been going public and securing funding to advance their re- search and drug pipelines in what could be described as a biotech boom. For many of these commercial companies, they turn to contract research organizations (CROs) and contract manufacturing organizations (CMOs) to help them get the job done. Additionally, the area’s life science research institutes have played a crucial role in meeting this mo- ment of industry growth and delivering innovative work that translates to healthcare solutions. The San Diego Business Journal connected with a few of the organizations that are supporting the life science industry and driving innovation. Helping Companies Scale In Q2 of this year, venture capital funding totaled $2 billion and almost half of these deals were with fast-grow- ing life science companies. In recent months, startups have received funding, M&A deals have popped up and more than 10 biotech companies have gone public through IPOs and SPAC mergers. Larger pharmaceutical companies often have the re- sources and manpower to conduct R&D operations in- house if they choose. With capital in hand, these smaller companies are moving fast and the need to scale leads many biotech companies to rely on contracting organi- zations to help them make it happen. For instance, Metacrine, a clinical-stage biopharma- Photo Courtesy of Ajinomoto Bio-Pharma Services ceutical company that specializes in therapies for patients Ajinomoto Bio-Pharma Services recently announced that it will open a high-speed multi-purpose fill-finish line in its state-of- with liver and gastrointestinal (GI) diseases, announced the-art commercial manufacturing facility in San Diego.
    [Show full text]
  • Wake Forest Journal of Business and Intellectual Property Law
    WAKE FOREST JOURNAL OF BUSINESS AND INTELLECTUAL PROPERTY LAW VOLUME 20 WINTER/SPRING 2020 NUMBER 2 FASTER SCIENCE: WHY SCIENTIST.COM’S BLOCKCHAIN APPROACH IS THE ANSWER TO THE PHARMACEUTICAL INDUSTRY’S 21 C.F.R. PART 11 COMPLIANCE CHALLENGES Kelly Kagan† ABSTRACT ............................................................................ 3 INTRODUCTION .................................................................... 3 I. BACKGROUND ................................................................... 9 A. BACKGROUND ON DRUG REGULATION ...................... 10 B. BACKGROUND ON PART 11 ......................................... 13 1. 1997 Introduction of Part 11 ..................................... 13 2. 2003 AMENDMENT TO PART 11 ..................................... 15 C. PART 11’S CURRENT CHALLENGES ............................ 17 1. New Drug Development and Outsourcing in a GloBal Market ............................................................. 17 2. FDA Warnings and Loss of Goodwill ....................... 27 3. Implications of an FDA Disapproval of an NDA ...... 29 4. Contracting and Material Breach ............................. 33 II. PREVIOUS SOLUTIONS HAVE FAILED .......................... 36 III. BLOCKCHAIN FACILITATES PART 11 COMPLIANCE .................................................................... 37 A. THE STRENGTHS OF BLOCKCHAIN .............................. 38 1. Blockchain Ensures Data Integrity By Ensuring Access and Change Controls ...................................... 38 2. Blockchain Reduces the Costs
    [Show full text]
  • Planning for Future Research in Public Universities in Uncertain Times
    Planning for Future Research in Public Universities in Uncertain Times Merrill Series on The Research Mission of Public Universities A compilation of papers originally presented at a retreat sponsored by The Merrill Advanced Studies Center July 2014 Mabel L. Rice, Editor Technical editor: Evelyn Haaheim MASC Report No. 118 The University of Kansas © 2014 The University of Kansas Merrill Advanced Studies Center or individual author TABLE OF CONTENTS MASC Report No. 118 Introduction Mabel L. Rice ..................................................................................................................... vi Director, Merrill Advanced Studies Center, the University of Kansas Executive summary ......................................................................................................... viii Keynote address Sally Frost Mason ........................................................................................................... 1 President, the University of Iowa Planning for Future Research in Public Universities in Uncertain Times Panel 1: Research Administrators Harvey Perlman ............................................................................................................. 19 Chancellor, University of Nebraska Engaging with the Private Sector: Nebraska Innovation Campus Brian Foster ...................................................................................................................... 25 Provost and Professor Emeritus, University of Missouri Adaptive Planning in a Chaotic Research Environment:
    [Show full text]
  • San Diego Business Journal Supplement
    SAN DIEGO BUSINESS JOURNAL SUPPLEMENT TITLE SPONSOR GOLD SPONSORS IN PARTNERSHIP WITH Page A16 www.sdbj.com MOST ADMIRED CEO SUPPLEMENT December 16, 2013 Access to Expertise Steadfast Relationships Comprehensive Solutions Financial Integrity Chase Congratulates the 2013 Most Admired CEOs. Chase Commercial Banking is committed to helping mid-sized businesses across San Diego achieve their goals. Chase offers you the local delivery of global capabilities and award-winning industry expertise. Just like you, your dedicated Chase banker is a part of San Diego and understands the unique needs of the businesses that operate here. Through our partnership, we will deliver tailored fi nancial solutions and fi rst-class client service that will position you for success. Chase takes pride in strengthening the communities we serve by helping local businesses thrive. Let us do the same for you. Contact Brennon Crist, San Diego Market Manager, Middle Market Banking at (619) 358-6361 or visit chase.com/commercialbanking for more information. COMMERCIAL BANKING © 2013 JPMorgan Chase & Co. All rights reserved. Chase, JPMorgan and JPMorgan Chase are marketing names for certain businesses of JPMorgan Chase & Co. and its subsidiaries worldwide (collectively, “JPMC”). Products and services may be provided by commercial bank affi liates, securities affi liates or other JPMC affi liates or entities. PA_13_464 December 16 , 2013 MOST ADMIRED CEO SUPPLEMENT www.sdbj.com Page A17 Letter From The San Diego Business Journal elcome to the San Diego Business Journal’s seventh annual Most Admired CEO publication. In the following pages we are pleased to present a repertoire of San Diego’s most dynamic and innovative business leaders.
    [Show full text]